Journal
BIOMEDICINES
Volume 10, Issue 4, Pages -Publisher
MDPI
DOI: 10.3390/biomedicines10040822
Keywords
metastatic melanoma; targeted therapy; immunotherapy; combined therapies; tumor relapse; tumor resistance
Ask authors/readers for more resources
Malignant melanoma is the leading cause of death among cutaneous malignancies. The introduction of immunotherapies and targeted therapies have contributed to a small decrease in mortality rate. However, toxicity and resistance remain critical challenges in the field.
Malignant melanoma is the leading cause of death among cutaneous malignancies. While its incidence is increasing, the most recent cancer statistics show a small but clear decrease in mortality rate. This trend reflects the introduction of novel and more effective therapeutic regimens, including the two cornerstones of melanoma therapy: immunotherapies and targeted therapies. Immunotherapies exploit the highly immunogenic nature of melanoma by modulating and priming the patient's own immune system to attack the tumor. Treatments combining immunotherapies with targeted therapies, which disable the carcinogenic products of mutated cancer cells, have further increased treatment efficacy and durability. Toxicity and resistance, however, remain critical challenges to the field. The present review summarizes past treatments and novel therapeutic interventions and discusses current clinical trials and future directions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available